The earnings call presents a generally positive outlook with significant revenue growth and expansion in implanting centers and sales territories. Improvements in reimbursement strategies and stable gross margins further contribute to the positive sentiment. However, challenges such as increased net loss, higher SG&A expenses, and rising interest expenses present areas of concern.

Company Guidance

In the CVRx Q2 2025 earnings call, the company provided financial guidance, predicting total revenue for the full year 2025 to be between $55 million and $57 million, with gross margins expected to remain steady between 83% and 84%. The company also projected operating expenses to range from $96 million to $98 million. For the third quarter of 2025, CVRx anticipates revenue to fall between $13.7 million and $14.7 million. The call highlighted the company's progress in expanding its sales force, which now includes more than 35% of territory managers hired since January, and the addition of 13 new active implanting centers in the U.S., bringing the total to 240. CVRx also announced significant reimbursement advancements, including CMS proposing to maintain Barostim's assignment to new technology APC 1580, and the anticipated transition to Category 1 CPT codes in January 2026, which is expected to improve reimbursement predictability and physician payment consistency. Additionally, the company emphasized its strategic focus on developing sustainable Barostim programs and enhancing clinical evidence to support Barostim's adoption as a standard of care in heart failure treatment.

Revenue Growth

Total revenue for Q2 2025 was $13.6 million, marking a 15% increase over the same quarter last year. U.S. heart failure revenue was $12.2 million, demonstrating continued growth in the U.S. heart failure business.

Expansion of Implanting Centers

The number of active implanting centers in the U.S. increased to 240 as of June 30, 2025, up from 227 at the end of Q1 2025.

Sales Force Transformation Progress

Sales territories in the U.S. increased to 47, with significant progress in the sales force transformation. More than 35% of territory managers were hired since January 1, and over half of the area sales directors have joined in the last 12 months.

Reimbursement Improvements

CMS proposed maintaining Barostim's assignment to new technology APC 1580 with approximately $45,000 payment for outpatient procedures. Transition to Category 1 CPT codes in January 2026 is expected to improve reimbursement predictability.

Gross Margin Stability

Gross margin remained stable at 84% for Q2 2025, consistent with the prior year period.

Increased European Revenue

Revenue generated in Europe was $1.3 million for Q2 2025, a 19% increase over the prior year period.

CVRx (CVRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CVRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2025 (Q3)	-0.50 / -	-0.57	―	―	―
Aug 04, 2025	2025 (Q2)	-0.52 / -0.57	-0.65	12.31% (+0.08)	―
May 08, 2025	2025 (Q1)	-0.57 / -0.53	-1.04	49.04% (+0.51)	―
Feb 04, 2025	2024 (Q4)	-0.38 / -0.43	-0.44	2.27% (+0.01)	―
Oct 29, 2024	2024 (Q3)	-0.50 / -0.57	-0.43	-32.56% (-0.14)	―
Jul 29, 2024	2024 (Q2)	-0.55 / -0.65	-0.56	-16.07% (-0.09)	―
Apr 30, 2024	2024 (Q1)	-0.54 / -1.04	-0.55	-89.09% (-0.49)	―
Jan 25, 2024	2023 (Q4)	-0.54 / -0.44	-0.51	13.73% (+0.07)	―
Oct 26, 2023	2023 (Q3)	-0.58 / -0.43	-0.48	10.42% (+0.05)	―
Jul 25, 2023	2023 (Q2)	-0.58 / -0.56	-0.54	-3.70% (-0.02)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CVRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 04, 2025	$7.55	$6.80	-9.93%
May 08, 2025	$7.78	$4.77	-38.69%
Feb 04, 2025	$16.25	$15.08	-7.20%
Oct 29, 2024	$10.74	$14.07	+31.01%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cvrx, Inc. (CVRX) report earnings?

Cvrx, Inc. (CVRX) is schdueled to report earning on Nov 04, 2025, After Close (Confirmed).

What is Cvrx, Inc. (CVRX) earnings time?

Cvrx, Inc. (CVRX) earnings time is at Nov 04, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CVRX EPS forecast?

CVRX EPS forecast for the fiscal quarter 2025 (Q3) is -0.5.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing